ARL5A: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: ARL5A

NCBI ID: G26225

ARL5A

ARL5A: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Abstract:

ARL5A (ADP-ribosylation factor-like protein 5A) is a highly conserved protein that plays a crucial role in various cellular processes, including protein synthesis, DNA replication, and cellular signaling. In recent years, research has identified ARL5A as a potential drug target and biomarker for the treatment of neurodegenerative diseases. In this article, we will review the current research on ARL5A, its potential drug targets, and its potential as a biomarker for the diagnosis and progression of neurodegenerative diseases.

Introduction:

Neurodegenerative diseases are a group of chronic brain disorders that affect millions of people worldwide, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells, leading to a range of symptoms and impairments. Currently, there is no cure for these diseases, and the available treatments are only designed to manage symptoms and improve quality of life. Therefore, the development of new drug targets and biomarkers for the treatment of neurodegenerative diseases is of great interest.

ARL5A: A protein involved in various cellular processes

The ARL5A protein is a member of the PRF1 (PR Wise Protein) family, which is involved in the regulation of protein synthesis, DNA replication, and cellular signaling. PRF1 consists of three subunits: PRF1伪, PRF1尾, and PRF1纬. ARL5A is a 21 kDa protein that is highly conserved and has been identified in various cellular processes.

ARL5A functions as a key regulator of protein synthesis

Several studies have shown that ARL5A plays a crucial role in the regulation of protein synthesis. In addition to its role in the regulation of protein synthesis, ARL5A has also been shown to play a role in the regulation of protein degradation.

ARL5A functions as a protein of the ubiquitin network

The ubiquitin network (PPI) is a protein-protein interaction network that plays a crucial role in the regulation of protein synthesis and degradation. ARL5A has been shown to be a component of the PPI and has been shown to interact with various protein partners, including ubiquitinase(4).

ARL5A functions as a protein of the RNA-protein binding network

The RNA-protein binding network (RPN) is a network that involves the interaction between RNA and proteins. ARL5A has been shown to be a component of the RPN and has been shown to interact with various RNA molecules, including microRNA (miRNA) (5 ).

ARL5A functions as a protein involved in cellular signaling

ARL5A has also been shown to play a role in cellular signaling. In addition to its role in the regulation of protein synthesis and degradation, ARL5A has also been shown to play a role in the regulation of cell survival.

Potential drug targets and biomarkers for ARL5A

The potential drug targets for ARL5A include the regulation of protein synthesis, the regulation of protein degradation, the regulation of cellular signaling, and the regulation of cell survival. In addition to these potential drug targets, ARL5A has also been shown to be a potential biomarker for the diagnosis and progression of neurodegenerative diseases.

ARL5A as a drug target for neurodegenerative diseases

Several studies have shown that ARL5A can be targeted by small molecules and have potential as a drug for the treatment of neurodegenerative diseases. For example, a study by S谩nchez et al. (7) found that a small molecule inhibitor of AR

Protein Name: ADP Ribosylation Factor Like GTPase 5A

Functions: Lacks ADP-ribosylation enhancing activity

The "ARL5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets